User login
Key clinical point: Dupilumab treatment was well-tolerated and demonstrated improved clinical and molecular responses in pediatric patients with moderate to severe atopic dermatitis (AD).
Major finding: Dupilumab significantly reduced Eczema Area and Severity Index, SCORing Atopic Dermatitis index, and Investigator’s Global Assessment scores at 3 and 6 months (all P < .05), along with significant reduction in AD-associated stratum corneum biomarker levels at 3 months (P < .01). Dupilumab showed good tolerability, with adverse events reported in only four patients.
Study details: This study included 314 pediatric patients with moderate to severe AD from the German TREATkids registry, of whom 87 received dupilumab.
Disclosures: TREATkids is the child and adolescent section of the TREATgermany registry, which is supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc., and Sanofi. Several authors declared receiving research grants, lecture, or consultancy fees from or having other ties with various sources, including the supporters of TREATgermany.
Source: Stölzl D, Sander N, Siegels D, et al, and the TREATgermany study group. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry. Allergy. 2024 (May 7). doi: 0.1111/all.16147 Source
Key clinical point: Dupilumab treatment was well-tolerated and demonstrated improved clinical and molecular responses in pediatric patients with moderate to severe atopic dermatitis (AD).
Major finding: Dupilumab significantly reduced Eczema Area and Severity Index, SCORing Atopic Dermatitis index, and Investigator’s Global Assessment scores at 3 and 6 months (all P < .05), along with significant reduction in AD-associated stratum corneum biomarker levels at 3 months (P < .01). Dupilumab showed good tolerability, with adverse events reported in only four patients.
Study details: This study included 314 pediatric patients with moderate to severe AD from the German TREATkids registry, of whom 87 received dupilumab.
Disclosures: TREATkids is the child and adolescent section of the TREATgermany registry, which is supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc., and Sanofi. Several authors declared receiving research grants, lecture, or consultancy fees from or having other ties with various sources, including the supporters of TREATgermany.
Source: Stölzl D, Sander N, Siegels D, et al, and the TREATgermany study group. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry. Allergy. 2024 (May 7). doi: 0.1111/all.16147 Source
Key clinical point: Dupilumab treatment was well-tolerated and demonstrated improved clinical and molecular responses in pediatric patients with moderate to severe atopic dermatitis (AD).
Major finding: Dupilumab significantly reduced Eczema Area and Severity Index, SCORing Atopic Dermatitis index, and Investigator’s Global Assessment scores at 3 and 6 months (all P < .05), along with significant reduction in AD-associated stratum corneum biomarker levels at 3 months (P < .01). Dupilumab showed good tolerability, with adverse events reported in only four patients.
Study details: This study included 314 pediatric patients with moderate to severe AD from the German TREATkids registry, of whom 87 received dupilumab.
Disclosures: TREATkids is the child and adolescent section of the TREATgermany registry, which is supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc., and Sanofi. Several authors declared receiving research grants, lecture, or consultancy fees from or having other ties with various sources, including the supporters of TREATgermany.
Source: Stölzl D, Sander N, Siegels D, et al, and the TREATgermany study group. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry. Allergy. 2024 (May 7). doi: 0.1111/all.16147 Source